Phillips Katharine A, Rasmussen Steven A
Butler Hospital, Providence, RI, USA.
Psychosomatics. 2004 Sep-Oct;45(5):438-44. doi: 10.1176/appi.psy.45.5.438.
In a 12-week placebo-controlled study of fluoxetine in the treatment of body dysmorphic disorder, the authors investigated change in psychosocial functioning and mental health-related quality of life in 60 subjects. The subjects were assessed with the LIFE-RIFT (a measure of impaired functioning), Social and Occupational Functioning Scale (SOFAS), and Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) before and after receiving fluoxetine or placebo. At baseline, the patients had impaired psychosocial functioning and markedly poor mental health-related quality of life. Compared to placebo, fluoxetine was associated with significantly greater improvement in LIFE-RIFT and SOFAS scores and with improvement on the mental health subscale of the SF-36 that approached significance. Decrease in the severity of body dysmorphic disorder, as measured by the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder, was significantly correlated with improvement in functioning and quality of life.
在一项为期12周的氟西汀治疗躯体变形障碍的安慰剂对照研究中，作者调查了60名受试者心理社会功能及心理健康相关生活质量的变化。在接受氟西汀或安慰剂治疗前后，使用LIFE-RIFT（功能受损测量工具）、社会和职业功能量表（SOFAS）以及医学结局研究36项简短健康调查（SF-36）对受试者进行评估。基线时，患者心理社会功能受损，心理健康相关生活质量明显较差。与安慰剂相比，氟西汀与LIFE-RIFT和SOFAS评分显著更大程度的改善相关，并且与SF-36心理健康子量表的改善接近显著水平。通过针对躯体变形障碍修改的耶鲁-布朗强迫症量表测量的躯体变形障碍严重程度的降低，与功能和生活质量的改善显著相关。
